Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA5 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07256301Phase 1Recruiting
- Sponsor
- Lan-Yi Therapeutics
- Start
- Jan 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of EA5 in paroxysmal nocturnal hemoglobinuria (PNH) (3 cohorts), sponsored by Lan-Yi Therapeutics. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 14 weeks. Started Jan 2024; status: recruiting.
02
Drugs
EA5
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07256301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256301.